Economic messages in prescription drug advertisements in I medical journals

Medical Care

Volumn 40, Issue 9, 2002, Pages 840-845

  Neumann, Peter J ^a,d   Bambauer, Kara Zivin ^a   Ramakrishnan, Vijay ^b   Stewart, Kate A ^a   Bell, Añd Chaim M ^c  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b Duke University   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Advertising; Cost effectiveness; Economic messages; Prescription drugs

Indexed keywords

DRUG;

ADVERTIZING; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG INDUSTRY; ECONOMICS; HUMAN; PUBLICATION;

ADVERTISING; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; HUMANS; PERIODICALS; PHARMACEUTICAL PREPARATIONS;

EID: 0036718487     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200209000-00013     Document Type: Article

References (30)

1. Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence Health Aff 2000;19:92-109.
2. Christensen D, Wertheimer A. Sources of information and influences on new drug prescribing among physicians in an HMO. Soc Sci Med 1979;13A:313-322.
3. Manning P, Denson T. How internists learned about cimetidine. Ann Intern Med 1980;92:690-692.
4. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
5. Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientific drug prescribing. Soc Sci Med 1989;28:577-582.
6. Aventis Pharmaceuticals. Managed Care Digest Series. Parsippany, NJ: Aventis Pharmaceuticals; 2000:23.
7. Poisal JA, Chulis GS. Medicare beneficiaries and drug coverage. Health Aff 2000;19:248-256.
8. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts'assessments. Ann Intern Med 1992;116:912-919.
9. Lexchin J, Holbrook A. Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. Can Med Assoc J 1994;151:47-54.
10. Landis RJ, and Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
11. Drug topics: Red Book. Montvale, NJ: Medical Economic; 1999.
12. Kessler DA. Addressing the problem of misleading advertising. Ann Intern Med 1992;116:950-951.
13. Code of Federal Regulations. Title 21: Food and Drugs. Part 202, Prescribing Drug Advertising. Washington, DC: U.S. Government Printing Office; 1981.
14. Burke L. US regulation of pharmaceutical outcomes research: can the past predict the future? Presentation at ISPOR 5th Annual Meeting. May 24, 2000.
15. Neumann PJ, Claxton K, Weinstein MC. The FDA's regulation of health economic information. Health. Aff 2000;19:129-137.
16. Stewart KA, Neumann PJ. FDA actions against misleading or unsubstantiated economic and quality-of-life claims: an analysis of warning letters and notices of violation. Value Health (in press).
17. Denig P, Haaijer-Ruskamp FM, Zisling DH. How physicians choose drugs. Soc Sci Med 1988;27:1381-1386.
18. Denig P, Haaijer-Ruskamp FM, Wesseling H, et al. Towards understanding treatment preferences of hospital physicians. Soc Sci Med 1993;36:915-924.
19. Epstein AM, Read JL, Winickoff R. Physicians beliefs, attitudes and prescribing behavior for antiinflammatory drugs. Am J Med 1984;77:313-8.
20. Shulkin D. The rising cost of pharmaceuticals: a physician's perspective. Am J Hosp Pharm 1993;50 (Suppl):S8-10.
21. Ryan M, Yule B, Bond C, et al. Scottish general practitioners' attitudes and knowledge in respect of prescribing costs. BMJ 1990;300:1316-1318.
22. Savafi KT, Hayward RA. Choosing between apples and apples: physicians' choices of prescription drugs that have similar side effects and efficacies. J Gen Intern Med 1992;7:32-37.
23. Denig P, Haaijer-Ruskamp FM. Do physicians take cost into account when making prescribing decisions. Pharmacoeconomics 1995;8:282-290.
24. Zelnio RN, and Gagnon JP. The effects of price information on physician prescribing patterns: a literature review. Drug intelligence and clinical pharmacy 1979;13:156-159.
25. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med 2000;160:2799-2803.
26. Mansfield PR. MaLAM: a medical lobby for appropriate marketing of pharmaceuticals. Med J Aust 1997;167:590-592.
27. Relman AS. Who reviews the ads? N Engl J Med 1979;301:999.
28. Rennie D. What responsibility do editors have for the advertisements in their journals. JAMA 1991;265:2394-2396.
29. Fletcher RH, Fletcher SW. Pharmaceutical advertisements in medical journals. Ann Intern Med 1992;116:951-952.
30. National Institute for Health Care Management Prescription drugs and mass media advertising, 2000. NHCM Foundation, Washington, DC, November 2001.